Skip to main content
MedPathMedPath Home
Clinical Trials/NCT00488670
NCT00488670
Terminated
Phase 3

An Open-label Study of Escitalopram in the Treatment of Major Depressive Disorder in Elderly Patients With Alzheimer's Disease

University of British Columbia2 sites in 1 country50 target enrollmentDecember 2010
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsDepressive Disorder
DrugsEscitalopram

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Depressive Disorder
Sponsor
University of British Columbia
Enrollment
50
Locations
2
Primary Endpoint
Change in Cornell Scale for Depression in Dementia (CSDD) from baseline.
Status
Terminated
Last Updated
14 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSitesSimilar Trials

Overview

Brief Summary

To investigate the effect of Escitalopram in a large and diverse of dementia patients suffering from depression.

Detailed Description

This study will assess the efficacy, tolerability, and safety of escitalopram in the treatment of Major Depressive Disorder in patients with Alzheimer's disease over a 24-week period. It will also assess the efficacy and tolerability of escitalopram after 12 weeks of treatment.

Registry
clinicaltrials.gov
Start Date
December 2010
End Date
June 2011
Last Updated
14 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •\> 50 years
  • •Male \& female
  • •Alzheimer's disease
  • •Depressive episode

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Change in Cornell Scale for Depression in Dementia (CSDD) from baseline.

Secondary Outcomes

  • Montgomery-Åsberg Depression Rating Scale; Neuropsychiatric Inventory; Alzheimer's Disease Cooperative Study

Study Sites (2)

Loading locations...

Similar Trials

Completed
Phase 3
Escitalopram (Lexapro®) In Patients With Major Depression With Atypical FeaturesAtypical Depression
NCT00610506Duke University15
Completed
Not Applicable
Progression Delaying Effect of Escitalopram in Alzheimer's DiseaseAlzheimer's Disease
NCT00702780Seoul National University Hospital74
Completed
Phase 4
A Safety and Efficacy Study of Escitalopram on Acute Treatment of Severe DepressionMajor Depressive Disorder
NCT01814085Xian-Janssen Pharmaceutical Ltd.225
Completed
Phase 4
Escitalopram for the Treatment of Depression in Alzheimer's DiseaseAlzheimer's Disease
NCT01841125Konkuk University Medical Center84
Completed
Not Applicable
Escitalopram in the Treatment of Postpartum DepressionPostpartum Depression
NCT01527474BC Women's Hospital & Health Centre20